PharmaSGP Holding SE Fundamental Analysis (XETRA: PSG.DE)
PharmaSGP Holding SE Fundamental Analysis (XETRA: PSG.DE)
PharmaSGP Holding SE (XETRA: PSG.DE) shows moderate financial fundamentals with a PE ratio of 17.58, profit margin of 16.44%, and ROE of 54.48%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 81.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze PSG.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentPSG.DE demonstrates superior asset utilization.
Valuation Score
ExcellentPSG.DE trades at attractive valuation levels.
Growth Score
ModeratePSG.DE shows steady but slowing expansion.
Financial Health Score
ExcellentPSG.DE maintains a strong and stable balance sheet.
Profitability Score
ExcellentPSG.DE achieves industry-leading margins.
Key Financial Metrics
Is PSG.DE Expensive or Cheap?
P/E Ratio
PSG.DE trades at 17.58 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PSG.DE's PEG of 1.78 indicates fair valuation.
Price to Book
The market values PharmaSGP Holding SE at 10.77 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 9.08 times EBITDA. This is generally considered low.
How Well Does PSG.DE Make Money?
Net Profit Margin
For every $100 in sales, PharmaSGP Holding SE keeps $16.44 as profit after all expenses.
Operating Margin
Core operations generate 23.26 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $54.48 in profit for every $100 of shareholder equity.
ROA
PharmaSGP Holding SE generates $17.09 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
PharmaSGP Holding SE produces operating cash flow of $24.12M, showing steady but balanced cash generation.
Free Cash Flow
PharmaSGP Holding SE generates strong free cash flow of $22.69M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.97 in free cash annually.
FCF Yield
PSG.DE converts 7.01% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.58
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.78
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.77
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.81
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.33
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.54
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
0.30
vs 25 benchmark
How PSG.DE Stacks Against Its Sector Peers
| Metric | PSG.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.58 | 32.02 | Better (Cheaper) |
| ROE | 54.48% | 569.00% | Weak |
| Net Margin | 16.44% | 29961.00% | Weak |
| Debt/Equity | 0.03 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 2.33 | 5.67 | Strong Liquidity |
| ROA | 17.09% | -96.00% (disorted) | Strong |
PSG.DE outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews PharmaSGP Holding SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation